HomeOpedVascular Surgeon in Ireland Views: The COVID-19 Cytokine Storm & the Novel Truth

Vascular Surgeon in Ireland Views: The COVID-19 Cytokine Storm & the Novel Truth

Professor Sherif Sultan offers his thoughts on the NICE UK Guidelines (Medical Device News Magazine)
Professor Sherif Sultan offers his thoughts on the COVID-19 Cytokine Storm and Novel Truth (Medical Device News Magazine)

Based on observations in the USA, Spain, Italy, France, and the UK, and from postmortem of lung involvement in COVID 19, all revealed pulmonary thrombosis, which is not typical ARDS. More alarming, was that patient hypoxemia was not responding to PEEP but high oxygen flow[1].

A Chinese scientist[2]  described the hypothesis of COVID 19, as methemoglobin, where COVID 19 virus structural protein, sticks to heme – displaces oxygen – which alters the iron-free ion, that leads to inflammation of alveolar macrophages which culminate to the systemic response ending in a cytokine storm. They suggested that free radical’s scavengers and iron-chelating agents if are added to the protocol of management might ameliorate the inflammatory response.

COVID 19, SARS2 is not ‘pneumonia’ nor ARDS. Invasive ventilation is the last resort, as emergency intubation from the Chinese, Italian and American experience had higher mortality, not to mention complications from tracheal scarring and stiff lung during the duration of intubation.  Furthermore, a new treatment protocol needs to be established in order to control the prolonged and progressive hypoxia of COVID191.

People are desaturating due to the failure of the blood to carry oxygen. This will lead to multi-organ failure and high mortality. The lung damage seen on CT scans is due to the oxidative stress released from the hemolysis red blood cells, which in turn overwhelm the natural defenses against pulmonary oxidative stress and cause Cytokine storm. There is always-bilateral ground-glass opacity in the lungs. Recurrent admission for post-hypoxic leukoencephalopathy fortifies the findings of the Italians, Spanish, and Americans3 that COVID-19 patients are suffering from metabolic hypoxia due to blood capacity failure.

The Chinese hypothesis2 that had been publicized that the following cascade might explain the vicious circle theoretically that the patient goes through

1) Without the iron ion, hemoglobin can no longer bind to oxygen. Once the hemoglobin is impaired, the red blood cell is essentially none functioning in carrying and delivering oxygen to any tissues. This leads to the destruction of the red blood cells and the patient’s oxygen saturation levels drop significantly.

COVID 19 patients, unlike CO poisoning in which eventually the CO can break off, the affected hemoglobin is permanently stripped of its ability to carry oxygen where the body compensates by secreting excess erythropoietin to stimulate the bone marrow to secrete new red blood cells.


References:

[1] https://time.com/5818547/ventilators-coronavirus/

[1] COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism Wenzhong Liu 1,2,*, Hualan Li2

#INVESTIGATIONALJOURNALISM #WHO #COVID19 #Cytokine

Please feel free to comment on this opinion.  The comment field can be found at the bottom of the page. 

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy